期刊文献+

万古霉素与β-内酰胺类联合对MRS的协同抗菌活性(英文) 被引量:4

Synergistic antimicrobial activities of vancomycin against methicillinresistant staphylococci in combination with β-lactams, rifampicin, gentamicin or erythromycin
下载PDF
导出
摘要 目的比较万古霉素与不同β-内酰胺类、利福平、庆大霉素和红霉素分别联合对34株耐甲氧西林葡萄球菌的协同抗菌活性。方法应用纸片扩散法测定不同抗生素纸片在脑心浸液琼脂板上的抑菌圈;棋盘协同试验应用琼脂稀释法;分数抑菌浓度指数由万古霉素与亚胺培南、苯唑西林和利福平联合获得的分数抑菌浓度的和。万古霉素与其它抗生素的协同作用包括青霉素、苯唑西林、头孢唑林、头孢他啶、亚胺培南、哌拉西林/三唑巴坦、庆大霉素和红霉素应用改良的纸片扩散法。结果万古霉素明显增加β-内酰胺类抗菌药物对6株耐甲氧西林葡萄球菌的抗菌活性,青霉素的抑菌圈直径增加最大,其他依次为苯唑西林、头孢唑林、亚胺培南、哌拉西林/三唑巴坦和头孢他啶,对红霉素和庆大霉素的抑菌圈基本无影响。棋盘法显示万古霉素与亚胺培南、苯唑西林和利福平的联合协同百分比依次为91.2%(31/34)、85.3%(29/34)和35.3%(12/34),对9株万古霉素异质性耐药葡萄球菌的协同百分比依次为100%、100%和33.3%。结论尽管万古霉素与利福平联合有协同作用,但不如万古霉素与β-内酰胺类抗菌药物联合的协同作用强。因此通过改良的纸片扩散协同试验选择与万古霉素最具协同作用的β-内酰胺类抗菌药物。 To compare the antibacterial effects of vancomycin against 34 clinical methicillin resistant Staphylococcus (MRS) strains, in the combination with different β-lactams, rifampicin, gentamicin or erythromycin. The inhibitory zone of antibiotics was determined by disk diffusion method in the brain heart infusion agar (BHIA). Checkerboard synergy testing was performed by the agar dilution method in the BHIA. The fractional inhibitory concentration (FIC) index was calculated by adding the FICs (MIC of drug A in combination with drug B/MIC in drug A alone) of vancomycin and oxacillin, imipenem and rifampicin, repectively. Synergy between vancomycin and other antibiotics including penicillin, oxacillin, cefazolin, ceftazidime, imipenem, piperacillin/tazobaetam, gentamiein, and erythromycin was also determined by a modified disk diffusion method. Disk diffusion test demonstrated that vancomycin could greatly enhance the antimicrobial activities of β-lactams against 6 strains of MRS. The diameter of the inhibitory zone of penicillin appeared to be the largest followed by those of oxacillin, cefazolin, imipenem, piperacillin/tazobactam and ceftazidime. Little or no enhancement effect by vaneomycin was seen on erythromycin and gentamicin. The checkerboard showed that the synergistic rates of vancomycin combined with imipenem, oxacillin or rifampicin against 34 MRS strains were 91.2% (31/34), 85.3% (29/34), and 35.3% (12/34) respectively. The mean synergic rate of the three combinations against 9 strains of heterogeneously vancomycin-resistant staphylococci was 100%, 100%, and 33.3% respectively. Results suggested although rifampicin in combination with vancomyicn was effective against MRS, it might not be considered as the first choice for such application because most of the tested β-lactams had showed better synergism with vancomycin in this study. The modified disk diffusion method could be used for screening available β-lactams to determine the best agents to pair with vancomycin for the control of MRS.
出处 《中国抗生素杂志》 CAS CSCD 北大核心 2006年第8期473-480,共8页 Chinese Journal of Antibiotics
基金 广东省卫生厅资助(项目编号A2002212)
关键词 万古霉素 葡萄球菌 抗菌活性 Β-内酰胺类 协同作用 Vancomycin Staphylococcus Antimicrobial activities β-lactams Synergism
  • 相关文献

参考文献29

  • 1Climo M W, Patron R L, Archer G C. Combinations of vancomycin and β-1actams are synergistic against staphylococci with reduced susceptibilities to vancomyicn[J]. Antimicrob Agents Chemother, 1999,43:1747
  • 2Boyce J M, Medeiros A A. Clinical isolates of methicillin-resistant Staphylococcus aureus from the United States with subpopulations of cells with reduced susceptibility to vancomycin, abstr. LB-15[A] In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy[C]. Washington, D C: American Society for Microbiology, 1997:6
  • 3Centers for Disease Control and Prevention. Update: Staphylococcus aureus with reduced susceptibility to vancomycin United States[J].Morbid Mortal, 1997, 46:813
  • 4Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility[J]. J Antimicrob Chemother, 1997,40:135
  • 5Ploy M C, Grelaud C, Martin C, et al. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital[J].Lancet , 1998, 351:1212
  • 6Centers for Disease Control and Prevention(CDC). Staphylococcus aureus resistant to vancomycin-United States, 2002[J]. MMWR Morb Mortal Wkly Rep, 2002, 51 (26): 565
  • 7Fraise A P. Guidelines for the control of methieillin-resistant Staphylococcus aureus[J]. J Antimicrob Chemother, 1998, 42:287
  • 8Michel M, Gutmann L. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: therapeutic realities and possi-bilities[J]. Lancet, 1997, 349:1901
  • 9Wu B Q, Tang Y C, Zhang K X, et al. Staphylococcus heterogeneously resistant to vancomyein in China and antimierobial activities of imipenem and vancomycin in combination against it[J]. J Clin Microbiol, 2002, 40(3): 1109
  • 10Barr J G, Smyth E T M, Hogg G M. In vitro antimicrobial activity of imipenem in combination with vancomycin or teicoplanin against Staphylococcus aureus and Staphylococcus epidermidis[ J]. Eur J Clin Microbiol Infect Dis, 1990, 9:804

同被引文献18

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部